Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 7/20 | 0.54 |
| ▸ | MET | P08581 | 10/20 | 0.53 |
| ▸ | FLT3 | P36888 | 3/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3544369 | 0.90 | MET (0.58) | AXLMETFLT3KDR | |
| SCHEMBL371861 | 0.88 | MET (0.51) | METFLT3KDR | |
| SCHEMBL5411428 | 0.86 | AXL (0.60) | AXLMETFLT3KDR | |
| SCHEMBL14279748 | 0.86 | ALOX5AP (0.44) | AXLMETFLT3KDR | |
| SCHEMBL168388 | 0.85 | AXL (0.71) | AXLMETFLT3KDR | |
| SCHEMBL371859 | 0.85 | AXL (0.65) | AXLMETFLT3KDR | |
| SCHEMBL29693573 | 0.85 | AXL (0.65) | AXLMETFLT3KDR | |
| SCHEMBL168510 | 0.84 | MET (0.47) | METKDR | |
| SCHEMBL15918385 | 0.83 | MET (0.70) | AXLMETFLT3KDR | |
| SCHEMBL13419698 | 0.82 | GPR119 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9186318-B2 | Quinolyl-containing hydroxamic acid compound and preparation method thereof, and pharmaceutical composition containing this compound and use thereof | BEIJING KONRUNS PHARMACEUTICAL CO., LTD (CN) | 2015-11-17 | — | — | US | disclosed |
| US-9186318-B2 | Quinolyl-containing hydroxamic acid compound and preparation method thereof, and pharmaceutical composition containing this compound and use thereof | BEIJING KONRUNS PHARMACEUTICAL CO., LTD (CN) | 2015-11-17 | — | — | US | disclosed |
| US-8999982-B2 | Pharmaceutically active compounds as Axl inhibitors | LEAD DISCOVERY CENTER GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| US-8999982-B2 | Pharmaceutically active compounds as Axl inhibitors | LEAD DISCOVERY CENTER GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| US-8999982-B2 | Pharmaceutically active compounds as Axl inhibitors | LEAD DISCOVERY CENTER GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| US-8933230-B2 | Phosphorus-containing group-substituted quinoline, its preparation process, medical composition containing the compounds and application | BEIJING KONRUNS PHARMACEUTICAL CO., LTD. (CN) | 2015-01-13 | — | — | US | disclosed |
| US-8933230-B2 | Phosphorus-containing group-substituted quinoline, its preparation process, medical composition containing the compounds and application | BEIJING KONRUNS PHARMACEUTICAL CO., LTD. (CN) | 2015-01-13 | — | — | US | disclosed |
| EP-2609091-B1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2014-11-26 | — | — | EP | disclosed |
| US-20140221425-A1 | Quinolyl-containing Hydroxamic Acid Compound and Preparation Method Thereof, and Pharmaceutical Composition Containing This Compound and Use Thereof | BEIJING KONRUNS PHARMACEUTICAL CO., LTD. (CN) | 2014-08-07 | — | — | US | disclosed |
| US-20140221425-A1 | Quinolyl-containing Hydroxamic Acid Compound and Preparation Method Thereof, and Pharmaceutical Composition Containing This Compound and Use Thereof | BEIJING KONRUNS PHARMACEUTICAL CO., LTD. (CN) | 2014-08-07 | — | — | US | disclosed |
| EP-2423208-A1 | Pharmaceutically active compounds as Axl inhibitors | Lead Discovery Center GmbH (DE) | 2012-02-29 | — | — | EP | disclosed |
| US-7732613-B2 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732613-B2 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732613-B2 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-08 | — | — | US | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
| WO-2007033196-A1 | MET KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-22 | — | — | WO | disclosed |
| US-20070060613-A1 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-15 | — | — | US | disclosed |
| US-20070060613-A1 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221425-A1 | Quinolyl-containing Hydroxamic Acid Compound and Preparation Method Thereof, and Pharmaceutical Composition Containing This Compound and Use Thereof | HDAC5, HDAC1, HDAC7 | AXL 2018/4885MET 1782/4885FLT3 304/4885 |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | HGF, ERBB2, MET | AXL 130/4885MET 3/4885FLT3 10/4885 |
| US-20070060613-A1 | Met kinase inhibitors | MET, ERBB2, ABL1 | AXL 562/4885MET 1/4885FLT3 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.